Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat switch study in pulmonary arterial hypertension with insufficient response to PDE-5 inhibitors
2013-001759-10Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Primary endpoint: No formal primary endpoint. Started Oct 2013; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2013-001759-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001759-10.